Department of Medicine, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Infect Immun. 2010 Jul;78(7):3027-35. doi: 10.1128/IAI.00264-10. Epub 2010 May 10.
Enterotoxigenic Escherichia coli (ETEC) causes considerable morbidity and mortality due to diarrheal illness in developing countries, particularly in young children. Despite the global importance of these heterogeneous pathogens, a broadly protective vaccine is not yet available. While much is known regarding the immunology of well-characterized virulence proteins, in particular the heat-labile toxin (LT) and colonization factors (CFs), to date, evaluation of the immune response to other antigens has been limited. However, the availability of genomic DNA sequences for ETEC strains coupled with proteomics technology affords opportunities to examine novel uncharacterized antigens that might also serve as targets for vaccine development. Analysis of whole or fractionated bacterial proteomes with convalescent-phase sera can potentially accelerate identification of secreted or surface-expressed targets that are recognized during the course of infection. Here we report results of an immunoproteomics approach to antigen discovery with ETEC strain H10407. Immunoblotting of proteins separated by two-dimensional electrophoresis (2DE) with sera from mice infected with strain H10407 or with convalescent human sera obtained following natural ETEC infections demonstrated multiple immunoreactive molecules in culture supernatant, outer membrane, and outer membrane vesicle preparations, suggesting that many antigens are recognized during the course of infection. Proteins identified by this approach included established virulence determinants, more recently identified putative virulence factors, as well as novel secreted and outer membrane proteins. Together, these studies suggest that existing and emerging proteomics technologies can provide a useful complement to ongoing approaches to ETEC vaccine development.
产肠毒素性大肠杆菌(ETEC)可引起发展中国家(尤其是幼儿)腹泻病,造成相当大的发病率和死亡率。尽管这些异质病原体具有全球重要性,但尚未开发出广泛保护的疫苗。尽管人们对具有良好特征的毒力蛋白(特别是不耐热毒素(LT)和定植因子(CFs))的免疫学有了很多了解,但迄今为止,对其他抗原的免疫反应评估仍然有限。然而,ETEC 菌株的基因组 DNA 序列的可用性以及蛋白质组学技术为检查可能作为疫苗开发目标的新型未表征抗原提供了机会。用恢复期血清分析全菌或分级细菌蛋白质组可以潜在地加速鉴定在感染过程中被识别的分泌或表面表达的靶标。在这里,我们报告了使用 ETEC 菌株 H10407 进行抗原发现的免疫蛋白质组学方法的结果。用感染 H10407 菌株的小鼠或感染 ETEC 后的恢复期人血清进行二维电泳(2DE)分离的蛋白质进行免疫印迹显示,在培养上清液、外膜和外膜囊泡制剂中存在多种免疫反应分子,表明在感染过程中存在许多抗原。通过这种方法鉴定的蛋白质包括已确立的毒力决定因素、最近鉴定的假定毒力因子以及新型分泌和外膜蛋白。总之,这些研究表明,现有的和新兴的蛋白质组学技术可以为 ETEC 疫苗开发的现有方法提供有用的补充。